Key Developments: TearLab Corp (TEAR.PH)
10.19USD
11:47am EDT
$0.08 (+0.79%)
$10.11
$10.18
$10.19
$10.16
600
--
--
--
Latest Key Developments (Source: Significant Developments)
TearLab Corp Announces Pricing Of Registered Financing
TearLab Corp announced that it has obtained commitments from two investors to purchase an aggregate of 2,500,000 shares of its common stock at a price of $3.17 per share for gross proceeds of approximately $7,925,000 in an underwritten registered financing. The proceeds of the offering will be used for working capital and general corporate purposes. The offering is expected to close on or about July 18, 2012. Full Article
TearLab Corp Announces Osmolarity Prevalence Study Presented At ASCRS 2012
TearLab Corp announced that at the American Society of Cataract and Refractive Surgery 2012 Annual Meeting in Chicago, IL, LASIK surgeon, Dr. Eric Donnenfeld, presented an interim analysis from a multicenter study designed to determine the overall prevalence of normal and abnormal tear fluid osmolarity in the patient population of clinicians who use the TearLab Osmolarity System. Normal tear film is in homeostasis with blood osmolarity at a reference value of 290 mOsm/L, with a normal homeostatic range for tear osmolarity defined as 275 - 307 mOsm/L. Hyperosmolarity is defined as a tear fluid osmolarity value in excess of the homeostatic range (greater or equal to 308 mOsm/L) in one or both eyes, and is used as a benchmark of dry eye disease (DED). The study involved 1,019 adult subjects (647 female, 372 male) from 16 sites across the United States and Europe. All patients in the study demonstrated at least three of the following nine binary symptoms: fluctuating vision, contact lens discomfort, light sensitivity, watery eyes, tired eyes, redness, burning, itching and sand or grit. The overall incidence of hyperosmolarity amongst the study population was 43.4%. Importantly, of the 42.4% of subjects who reported symptoms of DED, just 47.7% actually had the disease while 52.3% had some other form of ocular irritation. Conversely, of the 57.6% of study subjects that were asymptomatic, 40.2% actually had mild-to-moderate DED while 59.8% were within the normal homeostatic range. Full Article
TearLab Corporation Announces Closing Of Public Offering Of Common Stock Including Full Exercise Of Over-Allotment Option
TearLab Corporation announced that it has closed an underwritten public offering of 3 million shares of its common stock at a price to the public of $3.60 per share. Prior to the closing, the underwriter exercised in full the option to purchase an additional 450,000 shares of common stock at a price of $3.60 per share solely to cover over-allotments. The Company plans to use the approximately $11.3 million in total net proceeds for working capital and general corporate purposes. Craig-Hallum Capital Group LLC is acting as the sole book-running manager for the offering. Full Article
TearLab Corp Prices $10.8 Million Public Offering Of Common Stock
TearLab Corp announced that it has priced an underwritten public offering of 3 million shares of its common stock at a price to the public of $3.60 per share for gross proceeds of $10.8 million. The net proceeds from the sale of the shares, after deducting the underwriter's discounts and other estimated offering expenses payable by TearLab, will be approximately $9.8 million. The Company has also granted the underwriter a 30-day option to purchase up to an additional 450,000 shares of common stock offered in the public offering to cover overallotments, if any. The proceeds of the offering will be used for working capital and general corporate purposes. The offering is expected to close on or about April 16, 2012. Craig-Hallum Capital Group LLC is acting as the sole book-running manager for the offering. Full Article
TearLab Corp Announces Proposed Public Offering Of Common Stock
TearLab Corp announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. TearLab also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. The proceeds of the offering will be used for working capital and general corporate purposes. Craig-Hallum Capital Group LLC is acting as the sole book-running manager for the offering. Full Article
TearLab Corp Announces Osmolarity System CLIA Waiver Issued By FDA
TearLab Corp announced that, after reviewing and accepting labeling submitted to it by the Company, the U.S. Food and Drug Administration (FDA) has now granted Waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for the TearLab Osmolarity System. Full Article
TearLab Corp: FDA Grants TearLab Osmolarity System CLIA Waiver Categorization
TearLab Corp announced that it is in receipt of a communication from the U.S. Food and Drug Administration (FDA) indicating that, based on a supervisory review of the Company's appeal, the Agency has granted its petition for a waiver under CLlA for the TearLab Osmolarity System. Upon the Company's submission of labeling acceptable to the Agency, the CLIA waiver will be issued. The TearLab Osmolarity System uses a lab-on-a-chip approach that requires less than 50 nL (nanoliters) of tear fluid in order to measure tear Osmolarity. Full Article
TearLab Corp Closes USD7 Million Private Placement Of Common Stock And Warrants
TearLab Corp announced that it has closed its previously announced private placement of approximately 3.85 million units at a price of $1.82 per unit. Each unit consisted of one share of common stock and a warrant to purchase one share of common stock at an exercise price of USD1.86 per share. The Company has received total gross proceeds of approximately USD7 million. Piper Jaffray & Co. served as the sole lead placement agent and Roth Capital Partners served as co-placement agent for the transaction. Full Article
TearLab Corporation Announces USD7 Million Private Placement Of Common Stock And Warrants
TearLab Corporation announced that it has entered into a definitive agreement with certain institutional investors and members of its Board of Directors in connection with a private placement of approximately 3.85 million units at a price of $1.82 per unit. Each unit shall consist of one share of common stock and a warrant to purchase one share of common stock at an exercise price of USD1.86 per share. Gross proceeds from the private placement will be USD7 million. The private placement is expected to close on or about June 29, 2011 and is subject to customary closing conditions, including acceptance and approval by the Toronto Stock Exchange. Piper Jaffray & Co. served as the sole lead placement agent and Roth Capital Partners served as co-placement agent for the transaction. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
